Clinical trial
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
NCT00005934 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00005934 |
|---|---|
| Title | 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia |
| Official title | A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Beta Thalassemia |
| Intervention type | Drug |
| Interventions | 5-Azacytidine |
| Enrollment | 24 |
| Start date | Jun 1, 2000 |
| Completion | Jun 1, 2003 |
| First posted | Jul 7, 2000 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: